Elafibranor in Primary Biliary Cholangitis - A Comprehensive Review

Overview:

Elafibranor is a dual agonist that is being investigated for its ability to treat primary biliary cholangitis (PBC), a chronic liver disease marked by progressive bile duct damage. It is a PPARα/δ (peroxisome proliferator-activated receptors alpha and delta) dual agonist. Elafibranor has been demonstrated in clinical trials to considerably lower liver fibrosis and inflammation indicators, which may help PBC patients experience a slower rate of disease development. It provides a new mode of action by improving inflammation and lipid metabolism, which is important for people who do not react well to current therapies like Ursodeoxycholic acid (UDCA)—the FDA approval was on June 10, 2024.

How Does the Elafibranor Work?

The dual agonist Elafibranor acts on the alpha and delta peroxisome proliferator-activated receptors (PPARα/δ). It lowers liver fat and increases insulin sensitivity by increasing the metabolism of lipids and glucose through activating these receptors. Elafibranor protects the bile ducts and liver tissue from further damage by reducing inflammation and fibrosis in the setting of liver illnesses such as primary biliary cholangitis (PBC). It also modifies gene expression to lower the synthesis of fibrotic markers and pro-inflammatory cytokines. Elafibranor is a possible treatment option for chronic liver disorders where fibrosis and inflammation are major problems because of its dual effect.

What Are the Indications of Elafibranor?

• Primary Biliary Cholangitis (PBC): Elafibranor is being researched to treat primary biliary cholangitis (PBC), a chronic liver illness. It helps reduce inflammation and fibrosis, giving patients an alternative to first-line treatments like ursodeoxycholic acid (UDCA).

• Non-Alcoholic Steatohepatitis (NASH): Elafibranor is recommended for the treatment of non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD). It addresses fibrosis, fat deposition, and inflammation in the liver to prevent the progression of liver damage and enhance liver function.

• Dyslipidemia and Metabolic Syndrome: Elafibranor is being investigated to treat dyslipidemia and metabolic syndrome, disorders marked by elevated insulin resistance and aberrant cholesterol levels. This is because of its impact on lipid and glucose metabolism.

What Are the Contraindications of Elafibranor?

Because Elafibranor may exacerbate liver impairment or advanced liver disease and cause more liver dysfunction, it should not be administered to patients with these symptoms. Furthermore, since impaired kidney function can interfere with the drug's metabolism and excretion, raising the risk of toxicity, it is not advised for those with severe renal impairment. Furthermore, Elafibranor should not be administered to individuals with a history of recognized hypersensitivity to the medication or its ingredients to avoid serious allergic reactions. Due to possible dangers to the fetus or infant, Elafibranor should not be used during pregnancy or lactation as its safety in these situations has not been proven. Finally, Elafibranor should not be taken by people who have a history of serious cardiovascular illness because of its effects on lipid metabolism, which may hurt cardiovascular health, and call for caution in these patients.

Available Doses and Dosage Forms:

Dosage Forms

• Tablets: The most popular type, meant to be taken orally.

Accessible Doses

• 80 mg (Milligrams) Tablets: A less potent choice frequently utilized for certain patient needs or in the early stages of treatment.

• 120 mg Tablets: This larger dose is usually used for standard treatment plans in clinical studies and diseases, including non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).

For Patients

What Is Primary Biliary Cholangitis?

A chronic autoimmune liver disease called primary biliary cholangitis (PBC) is defined by the liver's tiny bile ducts gradually being destroyed. Due to the decreased bile flow brought on by this breakdown, bile builds up and damages liver cells, ultimately resulting in fibrosis and inflammation. If PBC is not treated, it can eventually lead to cirrhosis (a chronic liver disease marked by irreversible scarring and impaired liver function, often resulting from long-term damage such as alcohol abuse or viral hepatitis), liver failure (a critical condition where the liver loses its ability to perform vital functions, often due to severe damage or chronic disease progression), and the requirement for a liver transplant. Although weariness, pruritus (itching), and jaundice (a medical condition characterized by the yellowing of the skin and eyes due to elevated levels of bilirubin in the blood.) are common symptoms, the disease may not show any symptoms in the early stages. Although the precise origin of PBC is uncertain, genetic and environmental factors that produce an aberrant immune response against the bile ducts are thought to be involved. Blood tests that look for antimitochondrial antibodies (AMA) and increased liver enzymes are frequently used to diagnose PBC. Imaging and liver biopsy are also used to confirm the diagnosis. Common treatment options to enhance bile flow and reduce inflammation include Ursodeoxycholic acid (UDCA) and Obeticholic acid. Treatment generally focuses on treating symptoms and reducing the progression of the disease.

Why Is Elafibranor Prescribed?

Elafibranor is mostly prescribed to treat non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), two chronic liver illnesses. It stimulates peroxisome proliferator-activated receptors (PPARα/δ), which lessen fibrosis, enhance lipid metabolism, and lessen liver inflammation. These interventions can help people with these illnesses feel better, function better liver-wise, and see a reduction in symptoms. Patients who do not respond well to current treatments, such as Ursodeoxycholic acid (UDCA) for PBC, may find Elafibranor helpful. Elafibranor has also demonstrated promise in lowering cholesterol and increasing insulin sensitivity, two prominent metabolic issues linked to NASH and PBC. Its dual PPARα/δ activation addresses many disease pathways simultaneously, offering a holistic approach to liver health management. Its long-term advantages and safety profile are also being evaluated in ongoing clinical trials, which may broaden its therapeutic indications and strengthen its position as a crucial therapy option for chronic liver illnesses.

What Special Precautions Should Be Taken?

Because Elafibranor may impact liver enzymes, checking liver function periodically while taking the medication is crucial. Patients should avoid alcohol abuse because it can worsen liver damage. Healthcare professionals should evaluate all current drugs to prevent negative drug interactions, as Elafibranor may interact with other medications. Additionally, patients should be informed about the possibility of liver issues manifesting as jaundice, unexplained lethargy, or stomach pain, and they should promptly report any concerns to their healthcare physician.

What Are the Side Effects of Elafibranor?

Gastrointestinal side effects, such as nausea, diarrhea, and abdominal pain, are possible with Elafibranor. Liver enzyme levels may slightly rise in certain people; these should be checked frequently. There have also been reports of weariness and headache as adverse effects. Rarely, severe adverse effects, including severe liver damage or allergic reactions, may happen. If symptoms like severe abdominal discomfort, breathing difficulties, or yellowing of the skin or eyes appear, one should immediately see a doctor. Patients should immediately speak with their healthcare professional about any worries or strange symptoms.

Storage of Elafibranor:

Elafibranor should be kept at room temperature between 20 and 25 degrees Celsius (68 and 77 degrees Fahrenheit). It should be stored in its original container away from light and moisture. Elafibranor should not be kept in the bathroom or any other moist area. As directed by the pharmacist or local rules, prescription drugs should be stored out of the reach of children and pets. Any leftover or expired medication should also be disposed of properly.

For Doctors

Pharmacodynamics:

Elafibranor is an agonist that acts on the alpha and delta peroxisome proliferator-activated receptors (PPARα and PPARδ), which regulate inflammation, glucose homeostasis, and lipid metabolism. Elafibranor lowers the buildup of lipids in the liver and improves insulin sensitivity by activating these receptors, which increases the production of genes involved in fatty acid oxidation. Triglycerides are lowered, and high-density lipoprotein (HDL) cholesterol levels are raised, improving lipid profiles and reducing pro-inflammatory cytokine production. Because Elafibranor can reduce liver fibrosis and inflammation while accelerating the liver's ability to eliminate fat, it has been investigated clinically for the treatment of non-alcoholic steatohepatitis (NASH). Its pharmacodynamic actions also include lowering cardiovascular risk factors through enhanced metabolic characteristics, indicating that it is a viable treatment option for metabolic diseases linked to dysregulation of glucose and lipids.

Mechanism of Action:

Elafibranor is a dual agonist, activating alpha and delta peroxisome proliferator-activated receptors (PPARα/δ). These nuclear receptors control glucose homeostasis, lipid metabolism, and anti-inflammatory reactions. Elafibranor reduces lipid buildup and improves insulin sensitivity by activating PPARα, which increases fatty acid oxidation in the liver. Further anti-inflammatory effects and regulation of gene expression related to lipid metabolism and fibrosis are facilitated by activation of PPARδ. Because of its combined effects on reducing fibrosis, improving metabolic profiles, and reducing liver inflammation, Elafibranor is considered a possible treatment for illnesses such as non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).

Pharmacokinetics:

Absorption:

• Oral Bioavailability: Elafibranor absorbs readily orally, while meals may impact bioavailability. It is frequently advised to take it with food to improve absorption and lower variability.

• Peak Plasma Concentration (C_max): The medication achieves its peak plasma concentration two to four hours after delivery.

Distribution:

• The Volume of Distribution (V_d): Elafibranor's volume of distribution (V_d) is moderate, meaning it is dispersed throughout the body's tissues.

• Plasma Protein Binding: It has a high affinity for plasma proteins, especially albumin, and exhibits binding rates of over 99 percent. This indicates that the drug is only partially free to work as a therapeutic agent.

Metabolism:

• Hepatic Metabolism: Cytochrome P450 enzymes, especially CYP3A4 (Cytochrome P450 3A4), are the main enzymes in the liver that metabolize Elafibranor. CYP2C8 (Cytochrome P450 2C8) and CYP2C9 (Cytochrome P450 2C9) also play a minor role. It goes through oxidative metabolism, producing a range of metabolites.

• Metabolites: The primary metabolites have no pharmacological activity, suggesting that the parent chemical is predominantly responsible for the therapeutic effect.

Elimination

• Half-Life of Excretion: Elafibranor's elimination half-life is roughly five to seven hours, indicating that the medication leaves the body somewhat swiftly.

• Excretion Routes: It is eliminated by the biliary (feces) and renal (urine) channels. Thirty percent of the medicine and its metabolites are eliminated in the urine, and around sixty-seven percent are eliminated in the stools.

Toxicity:

Elafibranor's toxicity warrants careful evaluation, particularly in light of its function in the treatment of chronic liver illnesses. Although Elafibranor is generally well tolerated, it can elevate liver enzymes to a mild to moderate degree, which calls for routine monitoring to avoid potential hepatotoxicity. Among the most frequent adverse effects are digestive problems such as nausea, vomiting, and diarrhea, which might occasionally result in stopping treatment. Elafibranor has also been linked to slight elevations in blood creatinine, suggesting possible effects on renal function. Severe liver damage and hypersensitivity reactions, such as rash or breathing difficulties, are rare but serious side effects. Due to the drug's significant protein binding and metabolism, which predominantly occur in the liver, individuals who already have hepatic impairment should use caution when taking it.

What Are the Drug Interactions?

Interactions between Cytochrome P450 and CYP3A4 Substrates, Inhibitors, and Inducers:

• Substrates: CYP3A4 is responsible for the metabolism of Elafibranor. When used concurrently with other CYP3A4 substrates, such as statins or some antidepressants, the levels of these medications in the blood may change.

• Inhibitors: Elafibranor levels may rise when CYP3A4 inhibitors (such as Ketoconazole and Clarithromycin) are taken together, increasing the possibility of toxicity.

• Inducers: Medication that causes CYP3A4 induction, such as Carbamazepine and Rifampin, can lower Elafibranor levels and possibly lessen its effectiveness.

CYP Enzymes Other Than CYP2C8 and CYP2C9:

• Inhibitors: Elafibranor levels may rise when CYP2C8 (Cytochrome P450 2C8) and CYP2C9 (Cytochrome P450 2C9) inhibitors (such as Gemfibrozil and Fluconazole) are taken; hence, dosage modifications may be necessary.

Substances that Impact Lipid Metabolism

• Statins: By altering the metabolism of statins, Elafibranor can interact with them in ways that may raise the risk of muscle damage or change cholesterol levels.

Anticoagulants

• Warfarin: Elafibranor and warfarin may interact, changing the anticoagulant medication's effects. To prevent bleeding-related problems, it is advised to monitor INR (international normalized ratio) values.

Renal Manifestation

• Drugs Affecting Renal Function: Drugs that alter renal function, such as ACE (Angiotensin-Converting Enzyme (ACE) inhibitors or NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), may affect the renal excretion of Elafibranor. This could affect the drug's elimination and raise the risk of toxicity.

Use in Special Populations

• Pregnancy Considerations: Since Elafibranor's safety profile in pregnant women has not been proven, it is not advised to use it during pregnancy due to possible dangers to the developing fetus. To prevent potential injury to the fetus during Elafibranor treatment, women who are or may become pregnant should utilize an effective form of contraception.

• Breastfeeding Concerns: Since Elafibranor's presence in breast milk and its effects on a nursing infant are still unknown, it is not advised to take it during breastfeeding. If Elafibranor medication is required, breastfeeding should be stopped due to potential dangers to the newborn, including unknown effects on development and health.

• Pediatric Patients: Children should not take Elafibranor since its safety and effectiveness in treating pediatric patients have not been proven. Elafibranor prescriptions for pediatric patients should be made with caution and careful evaluation due to the lack of available data and potential dangers to growth and development.

• Geriatric Patients: Elafibranor prescriptions for elderly individuals require conscious thought and close observation because of possible aging-related changes in liver and kidney function. Some individuals may need to adjust their doses to guarantee safe and effective treatment and prevent an increased risk of side effects.